Abstract

High throughput sequencing (HTS) is increasingly important in determining cancer diagnoses, with subsequent prognostic and therapeutic implications. The biology of cancer is becoming increasingly deciphered and it is clear that therapy needs to be individually tailored. Whilst translational research plays an important role in lymphoid malignancies, few guidelines exist to guide biologists and routine laboratories through this constantly evolving field. In this article, we review the challenges of interpreting HTS in lymphoid malignancies and provide a toolkit to interpret single nucleotide variants obtained from HTS. We define the pre-analytical issues such as sequencing DNA obtained from formalin-fixed and paraffin-embedded tissue (FFPE), the acquisition of germline DNA, or the bioinformatic pitfalls, the analytical issues encountered and how to manage them. We describe the main constitutional and cancer databases, their characteristics and limitations, with an emphasis on variant interpretation in lymphoid malignancies. Finally, we discuss the challenges of predictions that one can make using in silico or in vitro modelling, pharmacogenomic screening, and the limits of those prediction tools. This description of the current status in genomic interpretation highlights the need for new large databases and international collaboration in the lymphoma field.

Highlights

  • Hematological malignancies, and in particular lymphoproliferative neoplasms, are characterized by considerable heterogeneity

  • The technological breakthrough of high-throughput sequencing (HTS) has provided valuable information, which is increasingly useful in the diagnostic workflow of lymphoproliferative neoplasms

  • The first challenges faced when dealing with HTS data from tumor tissues are to distinguish true sequence variations from technical artifacts, and to distinguish whether a variant is somatically acquired by the tumor or represents a germline variant that may or may not be implicated in tumorigenesis

Read more

Summary

Introduction

Hematological malignancies, and in particular lymphoproliferative neoplasms, are characterized by considerable heterogeneity. The technological breakthrough of high-throughput sequencing (HTS) has provided valuable information, which is increasingly useful in the diagnostic workflow of lymphoproliferative neoplasms. Mutational analysis of a panel of genes can help in the establishment of a diagnosis due to the specificity of particular mutations for a given entity (for example, the BRAF p.V600E mutation in hairy cell leukemia). There are many challenges that need to be overcome to ensure the optimal use of HTS in the diagnosis of lymphoid malignancies. The sequencing strategy should be adapted to the clinical needs; choosing an optimal panel is a compromise between clinical, economical, and practical considerations to ensure that the clinician will obtain reliable and relevant mutational data within a reasonable time. We will describe the existing databases and strategies that can help to deal with these issues

Is It a Somatic Variant?
Obtaining Germline DNA
Technical Considerations
Bioinformatic Aspects
Databases for Germline and Somatic Variants
Constitutional Databases
Cancer Databases
In Silico Modelling
In Vitro Modelling
Limits of Current Prediction Tools and Models to Predict the Clinical Impact
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call